NCT02503540View on ClinicalTrials.gov

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 18, 2015

Primary Completion Date

February 6, 2018

Study Completion Date

February 6, 2018

Conditions
Retinal Vein OcclusionDiabetic Macular EdemaBranch Retinal Vein OcclusionCentral Retinal Vein Occlusion
Interventions
DRUG

Aflibercept

Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.

Trial Locations (1)

44195

Cole Eye Institute, Cleveland Clinic, Cleveland

Sponsors

Lead Sponsor

Justis Ehlers
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Justis Ehlers

OTHER

NCT02503540 - Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO | Biotech Hunter | Biotech Hunter